Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids
Denise Beck, Insa Winzenborg, Mohan Liu, Jacob Degner, Nael M Mostafa, Peter Noertersheuser, Mohamad Shebley, Denise Beck, Insa Winzenborg, Mohan Liu, Jacob Degner, Nael M Mostafa, Peter Noertersheuser, Mohamad Shebley
Abstract
Background and objectives: Elagolix is an orally active, gonadotropin-releasing hormone receptor antagonist approved for the management of endometriosis-associated pain and heavy menstrual bleeding associated with uterine fibroids. Elagolix population pharmacokinetics and factors affecting elagolix exposure in healthy women and women with endometriosis have been reported previously. The purpose of this study was to extend the population pharmacokinetics model with additional modifications to incorporate data from phase III studies of elagolix with hormonal add-back therapy in women with uterine fibroids.
Methods: Data from 13 clinical studies (a total of 2168 women) consisting of six phase I studies in healthy premenopausal women, four phase III studies in premenopausal women with endometriosis, and three phase III studies in premenopausal women with uterine fibroids were analyzed using a non-linear mixed-effects modeling approach.
Results: Elagolix population pharmacokinetics was best described by a two-compartment model with first-order absorption, lag time in absorption, and first-order elimination. Out of the covariates tested on elagolix apparent clearance, apparent volume of distribution, and/or relative bioavailability, only organic anion transporting polypeptide 1B1 genotype status and body weight had a statistically significant but no clinically meaningful effect on elagolix relative bioavailability and apparent volume of distribution, respectively. There were no clinically meaningful differences in elagolix population pharmacokinetics in healthy women or women with endometriosis or uterine fibroids.
Conclusions: Elagolix population pharmacokinetics modeling did not reveal any patient-related factors or clinical parameters that would require dose adjustments for the approved dosage of 300 mg twice daily with estradiol 1 mg /norethindrone acetate 0.5 mg daily, in women with heavy menstrual bleeding associated with uterine fibroids.
Clinical trial registration: ClinicalTrials.gov identifiers: NCT01620528 (EM-1), NCT01760954 (EM-1-Extend), NCT01931670 (EM-2), NCT02143713 (EM-2-Extend), NCT02654054 (UF-1), NCT02691494 (UF-2), NCT0295494 (UF-Extend).
Trial registration: ClinicalTrials.gov NCT01620528 NCT01760954 NCT01931670 NCT02143713 NCT02654054 NCT02691494 NCT02925494.
Conflict of interest statement
DB, IW, ML, JD, NMM, PN, and MS are employees of AbbVie Inc. and may hold AbbVie stock and/or stock options.
© 2021. The Author(s).
Figures
References
- Ng J, Chwalisz K, Carter DC, Klein CE. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab. 2017;102(5):1683–1691. doi: 10.1210/jc.2016-3845.
- Orilissa™ (elagolix) [United States package insert]. North Chicago: AbbVie Inc.; 2018.
- Oriahnn™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules) [United States package insert]. North Chicago: AbbVie Inc.; 2020.
- Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol. 1992;166(2):740–745. doi: 10.1016/0002-9378(92)91706-G.
- Surrey ES. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show? Curr Opin Obstet Gynecol. 2010;22(4):283–288. doi: 10.1097/GCO.0b013e32833b35a7.
- Winzenborg I, Nader A, Polepally AR, Liu M, Degner J, Klein CE, et al. Population pharmacokinetics of elagolix in healthy women and women with endometriosis. Clin Pharmacokinet. 2018;57(10):1295–1306. doi: 10.1007/s40262-018-0629-6.
- Schlaff WD, Ackerman RT, Al-Hendy A, Archer DF, Barnhart KT, Bradley LD, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 2020;382(4):328–340. doi: 10.1056/NEJMoa1904351.
- Simon JA, Al-Hendy A, Archer DF, Barnhart KT, Bradley LD, Carr BR, et al. Elagolix treatment for up to 12 months in women with heavy menstrual bleeding and uterine leiomyomas. Obstet Gynecol. 2020;135(6):1313–1326. doi: 10.1097/AOG.0000000000003869.
- Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28–40. doi: 10.1056/NEJMoa1700089.
- Ng J, Duan WR, Marbury T, Schmidt JM, Klein CE. Elagolix pharmacokinetic profiles in women with renal or hepatic impairment. Clin Pharmacol Drug Dev. 2019;8(8):1053–1061. doi: 10.1002/cpdd.640.
- Shebley M, Polepally AR, Nader A, Ng JW, Winzenborg I, Klein CE, et al. Clinical pharmacology of elagolix: an oral gonadotropin-releasing hormone receptor antagonist for endometriosis. Clin Pharmacokinet. 2020;59(3):297–309. doi: 10.1007/s40262-019-00840-7.
- Polepally AR, Ng JW, Salem AH, Dufek MB, Parikh A, Carter DC, et al. Assessment of clinical drug–drug interactions of elagolix, a gonadotropin-releasing hormone receptor antagonist. J Clin Pharmacol. 2020;60(12):1606–1616. doi: 10.1002/jcph.1689.
- Taylor HS, Dun EC, Chwalisz K. Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain. Pain Manag. 2019;9(5):497–515. doi: 10.2217/pmt-2019-0010.
Source: PubMed